IAM
IPXL

Iridian Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Iridian Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-9,060
Closed -$272K – 119
2014
Q2 		$272K Sell
9,060
-3,730
-29% -$101K ﹤0.01% 58
2014
Q1 		$338K Sell
12,790
-2,160
-14% -$54K ﹤0.01% 76
2013
Q4 		$376K Buy
14,950
+2,910
+24% +$64.9K ﹤0.01% 106
2013
Q3 		$246K Hold
12,040
– – ﹤0.01% 128
2013
Q2 		$240K Buy
+12,040
New +$214K ﹤0.01% 125

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Iridian Asset Management's IPXL Position: Q3 2014 in Review

Iridian Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q3 2014, closing a stake of 9,060 shares — an estimated $272K sold.

Iridian Asset Management first reported a position in IPXL in Q2 2013 and held it in 5 quarters. The position peaked at $376K in Q4 2013. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

  • Iridian Asset Management reported no remaining Impax Laboratories, Inc. position as of Q3 2014 after selling out during the quarter.
  • Iridian Asset Management sold 9,060 Impax Laboratories, Inc. shares in Q3 2014, an estimated $272K.
  • Iridian Asset Management first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 5 quarters.
  • Iridian Asset Management's Impax Laboratories, Inc. position peaked at $376K in Q4 2013.
  • 162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on Iridian Asset Management's 13F filing for Q3 2014, filed 7 Nov 2014.